INDIANAPOLIS--(BUSINESS WIRE)--As 2025 draws to a close, Elevance Health highlights how today's health plans are evolving to better support their members in a broader range of situations that affect health, including cancer diagnoses, mental health crises, and unexpected health concerns during pregnancy. From employer-sponsored health insurance to government-sponsored programs, health plans are evolving to better support their members in a broader range of situations that affect health. In partnership with ...

OLDWICK, N.J.--(BUSINESS WIRE)-- #insurance--AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICRs) of "a+†(Excellent) of the core Blue Cross Blue Shield (BCBS)-branded insurance subsidiaries of Elevance Health, Inc. (Elevance) (Indianapolis, IN) [NYSE: ELV], as well as most of its non-Blue-branded subsidiaries. In addition, AM Best has upgraded the FSR to A (Excellent) from A- (Excellent) and the Long-Term ICR to "a+†(Excellent). ...

This story was originally published on Healthcare Dive. To receive daily news and insights, subscribe to our free daily Healthcare Dive newsletter. Dive Brief: Elevance has added a former Pfizer executive to its board, the latest addition of pharmaceutical industry veteran as the insurer focuses on building its pharmacy services. Amy Schulman will start as an independent director of Elevance effective Jan. 12, the insurer announced Wednesday. Schulman will serve on the board’s audit and finance committ ...

"Amy's appointment underscores our commitment to a strong, independent board with diverse perspectives and the right balance of experience and innovation,†added Peru. "As Elevance Health continues to execute its strategy, the board's refreshment process remains central to our mission of improving health outcomes while delivering sustainable, long-term value.†About Elevance Health, Inc. Elevance Health is a lifetime, trusted health partner whose purpose is to improve the health of humanity. The company sup ...

Elevance Health, Inc. (NYSE:ELV) is among the cheap healthcare stocks to buy heading into 2026. As of December 7, Elevance Health, Inc. (NYSE:ELV) has a ‘Buy’ or equivalent rating from slightly more than half of the analysts covering the stock. With a median price target of $394, the stock has an upside potential of 19.12%. On November 26, TD Cowen increased the price target on Elevance Health, Inc. (NYSE:ELV) to $400.00 from $380.00, with an unchanged ‘Buy’ rating on the stock, naming it as its “Best Ide ...

INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health announced today that it expanded access of its Virtual Assistant, a digital experience designed to help members easily access information, understand their benefits, and find care with confidence. Available through the Sydney Health app and Elevance Health–affiliated health plan websites, Virtual Assistant uses conversational technology to simplify healthcare navigation and improve engagement between members and their health plans. "At Elevance Hea. ...

Group 1 - The industry survey indicates that UnitedHealth Group (UNH) and its peers, including Cigna (CI), Humana (HUM), CVS Health (CVS), and Anthem (ELV), are facing rising costs, regulatory scrutiny, and investor concerns [1][2] - Healthcare provider groups have reported that promised prior authorization reforms have not yet been realized [1][2]

Core Viewpoint - Elevance Health (ELV) stock appreciated by 6% over the past two months, indicating a potential shift in market sentiment and a possible turnaround supported by strong performance [1] Group 1: Company Performance - The stock of Elevance Health has outperformed the benchmark, suggesting positive investor sentiment and confidence in the company's future prospects [1] Group 2: Analyst Background - The analysis is conducted by a senior derivatives expert with over 10 years of experience in asset management, focusing on equity analysis, macroeconomics, and risk-managed portfolio construction [1] - The expert has a background in both institutional and private client asset management, emphasizing multi-asset strategies with a focus on equities and derivatives [1] Group 3: Investment Philosophy - The goal of the analysis is to share insights and foster a collaborative environment among investors, promoting accessible and empowering investment strategies [1]

Core Insights - Elevance Health, Inc. operates as a health benefits company with a market cap of $74.7 billion, supporting consumers and communities throughout their healthcare journey [1][2] Company Overview - Elevance employs over 100,000 associates and serves millions, addressing a full range of health needs through an integrated approach and a digital health platform [2] Stock Performance - Elevance's stock has dropped 26.2% from its 52-week high of $458.75 on April 8, but has gained 9.2% over the past three months, outperforming the Nasdaq Composite's 7.8% gains during the same period [3] - Year-to-date, Elevance's stock has declined 8.2% and 15.8% over the past 52 weeks, while the Nasdaq has surged 20.2% in 2025 and 21.1% over the past year [4] Financial Results - Despite better-than-expected Q3 results, Elevance's stock dropped 1.2% following the earnings release on October 21. The company reported a 12% year-over-year increase in topline revenue to $50 billion, exceeding expectations by 1.2% [5] - Adjusted EPS for the quarter was $6.03, a 29.9% year-over-year decline, but surpassed consensus estimates by 21.1% [5] Peer Comparison - Elevance has underperformed compared to The Cigna Group, which saw a marginal 80 basis points increase year-to-date, but performed slightly better than Cigna's 16.9% drop over the past 52 weeks [6]

Core Insights - Elevance Health is enhancing healthcare by leveraging technology to create a more intuitive and personalized experience for health plan members [1] Group 1 - The company aims to simplify access to healthcare services [1] - Elevance Health is focused on building trust among its health plan members [1]